Wolverine: Research Formulation Profile

Wolverine is not a single molecule but a two-peptide formulation, and the two components are studied along different pathways. That separation is the reason they are combined: the preclinical literature examines BPC-157 for cytoprotective and angiogenic signaling and TB-500 for actin-cytoskeleton regulation and cell migration. This profile covers what the blend is, what each constituent contributes to the research picture, and where the pairing sits in the class. For how that class is organized, see the tissue-repair peptides overview.

What is Wolverine?#

Wolverine is a research formulation supplied as a single freeze-dried vial containing two distinct peptides. BPC-157 is a synthetic 15-residue peptide (a pentadecapeptide) whose sequence matches a fragment of a protein identified in gastric juice. TB-500 is a synthetic peptide based on the actin-binding region of thymosin β4. Because the two are combined at a defined peptide mass per vial rather than as one compound, the blend has no single molecular formula or molecular weight; its identity is the identity of its constituents, each of which carries its own verifiable chemical record.

What does each constituent contribute to the research picture?#

The reason to pair these two peptides is that they are studied along pathways that do not overlap. BPC-157 is investigated for cytoprotective and angiogenic signaling, a mechanism connected in the literature to the VEGFR2–nitric-oxide pathway across tendon, ligament, gut, and vascular models; its full research picture is in the BPC-157 profile. TB-500 is studied for actin-cytoskeleton regulation and cell migration, following from the actin-sequestering behavior of thymosin β4 and its fragments; the TB-500 profile covers that mechanism. One line of work is about protective signaling, the other about the machinery of cell movement, and both are preclinical.

What does the research literature study?#

There is no single body of literature on the blend as a unit; the research is on the two peptides individually, which is why a formulation profile reads as the sum of its parts rather than as one mechanism. BPC-157 appears in preclinical tissue-repair and angiogenesis models framed around cytoprotective signaling, work reviewed in the context of the brain–gut axis and VEGFR2–NO framing. TB-500 appears in cell-migration and wound-closure models driven by actin regulation, following from the actin-binding characterization of thymosin β4 and the structural account of how the parent protein sequesters G-actin. Pairing peptides that act on distinct pathways is the experimental premise, but the combined formulation has not itself been the subject of controlled study; each mechanism claim rests on the single-compound literature. As across the class, this work is conducted in cell culture and animal models and does not speak to effects in people.

Where Wolverine sits in the tissue-repair class#

The tissue-repair class Nexara tracks is organized by mechanism, and Wolverine is the minimal case of a mechanism-spanning blend: it holds exactly the two peptides whose non-overlap defines the class. BPC-157 covers protective and angiogenic signaling; TB-500 covers actin regulation and cell migration. That same pairing sits inside the larger four-compound KLOW formulation, which adds a copper-matrix arm (GHK-Cu) and an anti-inflammatory arm (KPV) on top of it. The side-by-side breakdown of Wolverine's two components is the dedicated comparison, BPC-157 vs TB-500.

Handling and storage#

Wolverine is supplied as a lyophilized solid and dissolved prior to use, the same as the single-compound catalog. Because it is a co-lyophilized pair rather than one peptide, handling follows the general practice for research blends. The reconstitution primer covers solvent selection and avoiding aggregation, and the cold-chain article covers how stability changes once a multi-peptide powder is in solution.

Sources and further reading#

• Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (PMID 29444275): a review of BPC-157 preclinical research covering the cytoprotective and angiogenic (VEGFR2–NO) signaling framing for the blend's BPC-157 component.
• Actin-sequestering ability of thymosin β4 and its fragments (PMID 8471179): primary characterization of the actin-binding behavior underlying the blend's TB-500 component.
• Structural basis of thymosin-β4/profilin exchange in actin polymerization (PMC4217450): structural account of how thymosin β4 sequesters G-actin, the mechanism the TB-500 component is derived from.
• Thymosin beta-4, UniProt P62328: canonical sequence and annotation for the parent protein of the TB-500 component.
• BPC-157, PubChem CID 9941957: chemical identity record for the pentadecapeptide component.